A
Alex R. Rinehart
Researcher at Research Triangle Park
Publications - 41
Citations - 1633
Alex R. Rinehart is an academic researcher from Research Triangle Park. The author has contributed to research in topics: Cabotegravir & Medicine. The author has an hindex of 18, co-authored 33 publications receiving 1086 citations. Previous affiliations of Alex R. Rinehart include Durham University & ViiV Healthcare.
Papers
More filters
Journal ArticleDOI
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
Raphael J. Landovitz,Deborah Donnell,Meredith E. Clement,Brett Hanscom,Leslie Cottle,Lara E. Coelho,Robinson Cabello,Suwat Chariyalertsak,Eileen F. Dunne,Ian Frank,Jorge A Gallardo-Cartagena,Aditya H Gaur,Pedro Gonzales,Ha V Tran,Juan C Hinojosa,Esper G Kallas,Colleen F Kelley,Marcelo H. Losso,J Valdez Madruga,Keren Middelkoop,Nittaya Phanuphak,Breno Santos,Omar Sued,Javier Valencia Huamaní,Edgar T. Overton,Shobha Swaminathan,Carlos del Rio,Roy M. Gulick,Paul G. Richardson,Philip Sullivan,Estelle Piwowar-Manning,Mark A. Marzinke,Craig W. Hendrix,Maoji Li,Zhe Wang,Jeanne M. Marrazzo,Eric S. Daar,Aida Asmelash,Todd T. Brown,Peter J. Anderson,Susan H. Eshleman,Marcus Bryan,Cheryl Blanchette,Jonathan Lucas,Christina Psaros,Steven A. Safren,Jeremy Sugarman,Hyman M. Scott,Joseph J. Eron,Sheldon D. Fields,Nirupama Sista,Kailazarid Gomez-Feliciano,Andrea Jennings,Ryan Kofron,Timothy H. Holtz,Katherine Shin,James F. Rooney,Kimberly Y. Smith,William Spreen,David J. Margolis,Alex R. Rinehart,Adeola Adeyeye,Myron S. Cohen,Marybeth McCauley,Beatriz Grinsztejn,Hptn (PopART) Study Team +65 more
TL;DR: In this paper, safe and effective long-acting injectable agents for preexposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection are needed to increase the options for preve...
Journal ArticleDOI
A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy.
Calvin J. Cohen,Susan Hunt,Michael Sension,Charles Farthing,Marcus A. Conant,Susan Jacobson,Jeffrey P. Nadler,Werner Verbiest,Kurt Hertogs,Michael H. Ames,Alex R. Rinehart,Neil M.H. Graham,Roberto C. Arduino,Carol L. Brosgart,Stephen Brown,Ann C. Collier,Steven Davis,Jeffrey Galpin,Jeffrey Goodgame,Howard Grossman,W. Keith Henry,Harold A. Kessler,Martin Markowitz,Douglas L. Mayers,Michael S. Saag,Shannon Schrader,Allan Stein,Richard Stryker,Melanie A. Thompson,Gabriel Torres,Deborah Copeland +30 more
TL;DR: Antiretroviral treatment guided prospectively by PRT led to the increased use of ‘active’ antireTroviral agents and was associated with a significantly better virological response.
Journal ArticleDOI
Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial
Martin Markowitz,Ian Frank,Robert M. Grant,Kenneth H. Mayer,Richard Elion,Deborah Goldstein,Chester Fisher,Magdalena E. Sobieszczyk,Joel E. Gallant,Hong Van Tieu,Winkler G. Weinberg,David A. Margolis,Krischan J Hudson,Britt Stancil,Susan L. Ford,Parul Patel,Elizabeth Gould,Alex R. Rinehart,Kimberly Y. Smith,William Spreen +19 more
TL;DR: Despite high incidence of transient, mild-to-moderate injection-site reactions, long-acting cabotegravir was well tolerated with an acceptable safety profile and Pharmacokinetic data suggest that 800 mg administered every 12 weeks is a suboptimal regimen; alternative dosing strategies are being investigated.
Journal ArticleDOI
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial
Raphael J. Landovitz,Sue Li,Beatriz Grinsztejn,Halima Dawood,Albert Y. Liu,Manya Magnus,Mina C. Hosseinipour,Ravindre Panchia,Leslie Cottle,Gordon Chau,Paul G. Richardson,Mark A. Marzinke,Craig W. Hendrix,Susan H. Eshleman,Yinfeng Zhang,Elizabeth E. Tolley,Jeremy Sugarman,Ryan Kofron,Adeola Adeyeye,David N. Burns,Alex R. Rinehart,David Margolis,William Spreen,Myron S. Cohen,Marybeth McCauley,Joseph J. Eron +25 more
TL;DR: In this study, CAB LA was well tolerated at the doses and dosing intervals used and was not detectable in plasma both at the time of first reactive HIV test and at the study visit 12 weeks prior to the first reactive test.
Journal ArticleDOI
A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects.
Boris Gruzdev,A Rakhmanova,Ekaterina Doubovskaya,Alexey Yakovlev,Monika Peeters,Alex R. Rinehart,Karin de Dier,Patricia Baede-Van Dijk,Wim Parys,Gerben van 't Klooster +9 more
TL;DR: TMC125 was well tolerated and represents a promising and highly potent, next generation non-nucleoside reverse transcriptase inhibitor candidate in antiretroviral-naive, HIV-1-infected subjects.